4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.

Key facts

Study ID

NCT03538743

Run by

Pfizer

People needed

98

Starts

2018-06-25

Expected to finish

2019-06-10

Last updated by the study team

2020-07-01

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes treated with a stable dose of metformin at least 500 mg
• HbA1c value between 7.0 and 10.5%

You may not qualify if…

• Type 1 diabetes or secondary forms of diabetes

Where it is running

• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• Qps-Mra, Llc — South Miami, Florida, United States
• Qps-Mra,Llc — South Miami, Florida, United States
• Altasciences Clinical Kansas, Inc. — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.